Boehringer Ingelheim was an early adopter of Medidata's electronic data collection (EDC) platform for clinical trials, and has now extended and expanded the contract.
GSK has said it will not be able to move ahead with regulatory filings for otilimab as a treatment for rheumatoid arthritis (RA), after it failed to show the desired level of efficacy in tw
Boehringer Ingelheim has moved one of its top pipeline prospects – oral phosphodiesterase 4B (PDE4B) inhibitor BI 1015550 – into late-stage clinical testing for idiopathic pulmonary fibrosi
AstraZeneca seems to have dodged the problems besetting other developers of oral selective oestrogen receptor degrader (SERD) drugs with a phase 2 win for its candidate camizestrant in a ph